

The Effect of Biological Heterogeneity on R-CHOP Treatment Outcome in Diffuse Large B-cell Lymphoma Across Five International Regions

Authors

Robert Carr¹, Hilal Ozdag², NilgunTekin², Timothy Morris³, Paulette Conget⁴, Flavia Bruna⁴,
Botond Timar⁵, Eva Gagy⁵, Ranjan Basak⁶, Omkar Naik⁶, Chirayu Auewarakul⁷,
Narongrit Srithana⁷, Mark Pierre Dimaymay⁸, Filipinas Natividad⁸, June-Key Chung⁹,
Nevin Belder², Isinsu Kuzu¹⁰, Nader Omidvar¹¹, Diana Paez¹², Rose Ann Padua¹³,
on behalf of the IAEA Lymphoma Study Group

Affiliations

¹ Dept Haematology, Guy's & St Thomas' Hospital, King's College, London, UK,

² Biotechnology Institute, Ankara University, Ankara, Turkey,

³ Medical Research Council Clinical Trials Unit, University College London, UK ,

⁴ Facultad de Medicina Clínica Alemana - Universidad del Desarrollo Santiago, Chile,

⁵ 1st Department of Pathology and Experimental Cancer Research, Semmelweis University,
Budapest, Hungary

⁶ Dept Medical Oncology and Pathology, Tata Memorial Hospital, Mumbai, India,

⁷ Chulabhorn Cancer Centre, Siriraj Hospital, Bangkok, Thailand,

⁸ Research and Biology Division, St Luke's Medical Centre Manila, Philippines,

⁹ Oncology Clinic, Seoul National University Hospital, Seoul, Republic of Korea,

¹⁰ Dept Pathology, Ankara University, Ankara, Turkey

¹¹ Dept Haematology, University of Cardiff, UK

¹² Nuclear Medicine Section, International Atomic Energy Agency, Vienna, Austria,

¹³ INSERM 1131, University Paris-Diderot, Hôpital Saint-Louis, Paris, France.

Corresponding Author

Robert Carr MBChB

Department of Haematology, Guy's & St Thomas' Hospital, King's College, London.

Tel: 44 207 188 1431

Fax: 44 207 188 2748

Email: robtcarr@gmail.com

Running Title: Biological diversity and lymphoma survival

Key Words: DLBCL, Gene expression, Risk stratification, Prognosis

ABSTRACT

Addressing the global burden of cancer, understanding its diverse biology, and promoting appropriate prevention and treatment strategies around the world has become a priority for the United Nations and International Atomic Energy Agency (IAEA), the World Health Organisation, and International Agency for Research on Cancer (IARC). The IAEA sponsored an international prospective cohort study to better understand biology, treatment response, and outcomes of diffuse large B-cell lymphoma (DLBCL) in low and middle-income countries across five UN-defined geographical regions. We report an analysis of biological variation in DLBCL across seven ethnic and environmentally diverse populations. In this cohort of 136 patients treated to a common protocol, we demonstrate significant biological differences between countries, characterised by a validated prognostic gene expression score ($p < 0.0001$), but International Prognostic Index-adjusted survivals in all participating countries were similar. We conclude that DLBCL treatment outcomes in these populations can be benchmarked to international standards, despite biological heterogeneity.

INTRODUCTION

Cancer centres around the world may wish to compare their results against published studies from high-income Caucasian populations. Attempts to produce similar remission and survival rates across diverse populations may not be achievable if disease biology differs in low or middle income countries. Biological variation may arise from ethnic diversity which may influence host response, or the physical or microbiological environment which may influence causation and disease biology.

The International Atomic Energy Agency (IAEA) sponsored a prospective cohort study of diffuse large B-cell lymphoma (DLBCL) in countries from five United Nations defined geographical regions [1]. The study had two pre-defined aims: the first to investigate whether there was inter-country heterogeneity in speed of response, as assessed by positron emission tomography (PET), as a predictor of future survival; the second, to explore whether the biological characteristics of DLBCL differ and influence outcomes between countries. Analysis of the 327 patients with complete data for the PET monitoring component of the study has recently been reported [2]. We report here the analysis of between country biological heterogeneity and relate this to survival.

MATERIALS and METHODS

Patients and Treatment

The protocol was developed by the IAEA with all international collaborators between 2006-2008. Adults >16y with newly diagnosed DLBCL were recruited at major cancer centres in seven countries in Western Europe, Central Asia, South Asia, South East Asia and South America, during 2008-2012. Treatment was with a common chemotherapy protocol: Cyclophosphamide, Adriamycin, Vincristine, Prednisolone with Rituximab (R-CHOP), delivered at 21 day intervals. Omission of rituximab was permitted in a small number of patients who might otherwise have been excluded for financial reasons [2].

Treatment Response Assessment

Treatment response was based on international criteria [3]. To accurately adjust outcomes for IPI, pre-treatment staging was based on CT and PET imaging in all centres, and final response status was based on central reading of all end-treatment PET scans at a final investigator meeting, as previously described [2]. Event-free survival (EFS) at the validated time-point of 24 months was used as the comparative outcome measure [4]. We do not report overall survival, as this is strongly influenced by the variable approaches between countries to salvaging those who relapse. The common study protocol and assessment of outcomes has been described in greater detail elsewhere [2].

Measure of Biological Diversity

As the measure of biological variation, we used the 6-gene-expression score for predicting survival of patients with DLBCL, first published in 2004 by Losses et al. [5]. This 'mortality score' is derived from expression levels of 6 informative genes (3 predictive of better survival *LM02*, *BCL6*, *FN1*, and 3 of worse survival *CCND2*, *BCL2*, *SCYA3*) which together stratified patients into low, medium and high risk groups. When considered as a continuous variable the 6-gene score predicted overall survival for patients treated with CHOP [5] and both overall and progression free survival in a larger cohort treated with R-CHOP [6].

Molecular Methods

RNA was extracted from formalin-fixed diagnostic tissue [6] and sent to a central laboratory (Biotechnology Institute, Ankara University, Turkey) for analysis. Analyses were all performed by authors NT and HO.

RNA, 1000ng, was used to synthesize cDNA using ABI High-Capacity cDNA Reverse Transcription in 100µl, and 2µl (20ng/µl) cDNA used for each QPCR reaction. Standard curves were prepared from plasmids containing the cloned target genes. Taqman QPCR assays of the 6 genes plus ABL were conducted on a Light Cycler 480 platform (Roche, Germany) using standard methodology. Expression ratios were calculated based on delta

delta Ct²⁶ R=2(-ΔΔCT). The 6-gene score was calculated as originally described [4,5] and included in analyses as a continuous variable.

Statistical Methods

The analysis used a Cox model to stratify by country and initially included the 6-gene score, International Prognostic Index (IPI) and rituximab exposure as relevant predictive variables. However, as this model did not converge sufficiently due to few events per parameter, the final analysis investigated each variable separately in a Cox model stratified by country.

Research Governance

The study was approved by the relevant Research Ethics Committee, or Institutional Review Board in each participating centre. All patients were recruited into the study after gaining informed consent. Biological material and data were shared between countries only identified by a study code number and with all personal identifiers removed.

Role of the Funding Source

The IAEA provided funding which made the study possible, but had no role in the design, analysis or interpretation of the data, nor the decision to publish.

RESULTS

Complete molecular and clinical data were available for 136 patients. Sixty one were from high-income countries (Chile, Hungary, South Korea), 40 from upper-middle income countries (Thailand, Turkey), 35 from lower-middle income countries (India, Philippines) (table 1). There was good compliance with the common treatment protocol and 114/136 (84%) of all patients received rituximab (table 1).

At a median follow up of 2y and 6 months, 2y EFS for the 136 patients was 74% (95% Confidence Interval 65-84%), similar to the 2y EFS recently reported from a large UK R-CHOP trial, 75% (71-78%) [7]. There was moderate variation between individual countries, from 85% 2y EFS in Chile to 56% in Turkey (figure 1)

The distribution of individual gene expression varied significantly between countries ($P < 0.0001$) (figure 2a). When combined into the 6-gene score there similarly was significant between-country heterogeneity ($P < 0.0001$) (figure 2b). The distribution of 6-gene scores within and between countries did not suggest any association with geographical region or country economic status.

Our interest was to investigate whether the highly significant between-country variation in the 6-gene prognostic score might explain the observed differences in event-free survivals. Multivariate analysis found only the IPI to be a significant predictor of outcome ($P = 0.009$), whereas neither the 6-gene score ($P = 0.21$), nor variation in use of rituximab between countries ($P = 0.08$) were significant explanatory factors.

To gain further insight into how adjustment for IPI or 6-gene score might individually influence the relative 2y EFS between countries, Kaplan-Meier plots were generated from the Cox analyses, including country as a co-variate rather than stratifying variable. Within each country individual patient outcomes were normalised to remove the positive or negative influence of either the 6-gene score or IPI on EFS, then plotted as an adjusted survival curve. Composite figures displaying these modelled survival curves by country, without adjustment, adjusted for IPI or adjusted for 6-gene score are shown (figure 3)

Compared to the unadjusted 2y EFS (figure 3a), adjustment for IPI (figure 3b) brings the survival curves closer together, with little difference at 2 years between Chile, Hungary, S. Korea and Thailand. The survival curves for India, Philippines and Turkey form a second cluster with comparatively inferior 2y EFS. This figure reveals Turkey to have markedly improved 2y survival after adjustment for IPI, reflecting the high proportion of high IPI cases. India and Philippines have 2y EFS approximately 15% lower than Chile, Hungary and S.Korea, reflecting the lower use of rituximab (table 1). By contrast, adjustment for the 6-gene score (figure 3c) failed to bring the individual country survival curves closer together, thus demonstrating that variation in disease biology made no perceptible contribution to event-free survival differences between countries.

DISCUSSION

The goal for oncologists in emerging economies is to achieve cancer outcomes comparable to the developed world [8]. The effects of late presentations with advanced disease, or reduced resources for expensive treatments are recognised challenges that may confound direct comparisons. The possible influence of variable biology across continents, even within the single histological entity of this commonest of lymphomas is currently unknown.

Global variation in the prevalence of different NHL sub-types is well recognised [8]. The effect of environmental factors on DLBCL incidence, including levels of UV irradiation and infections have recently been reviewed and EBV associated with DLBCL is recognised as conferring poorer prognosis [10-13]. More recently, different inflammatory gene signatures within DLBCL tissue has been reported between Scandinavian and Egyptian cohorts [14].

When designing this biological component of the IAEA DLBCL study, an important consideration was selection of biological markers with proven relationship to survival, and which could be assayed using RNA from fixed tissue in a central laboratory. The 6-gene prognostic algorithm described by Lossos [5] had recently been published and had the merit of using standard methodology. Though initially devised for individual patient risk stratification, we used it as a global index of biological variation.

Though of lesser prognostic value in patients treated with immunochemotherapy [15], the intention had been to also include classification of cases as ABC or GCB subtypes. However this proved impracticable due lack of resources for the necessary establishment of between centre consistency in immuno-histocytochemistry, or central processing and reporting of all diagnostic biopsy sections [16].

The more recent 6-gene score study by Malumbres and colleagues [6] examined its relationship to outcomes of 132 patients treated with R-CHOP in 3 centres from North America, Canada and Spain. The authors did not report any between-centre heterogeneity in gene scores, but found in this population that, as in ours, IPI was the most significant

predictor of individual progression-free survival. However, the cohort was more homogeneous than ours in terms of ethnicity and socio-economic background and, in contrast to ours, demonstrated identical unadjusted 2y survival at the 3 centres.

No study, to our knowledge, has documented biological heterogeneity across a wide range of socio-economic environments or ethnically diverse populations, and related this to outcomes.

Understanding the influence of variable disease characteristics between countries is an essential step in the global effort to improve lymphoma outcomes. Our study confirms the existence of significant biological heterogeneity between the populations investigated. It is to be hoped that in the future more detailed analysis of genetic variation may be exploited to give insights into the causation of this common lymphoma.

For clinicians internationally, we have demonstrated that when adjusted for the International Prognostic Index, event-free survivals for diffuse large B-cell lymphoma are comparable across seven socio-economic and ethnically diverse countries, despite significant differences in a validated prognostic gene-expression score. Where treatment includes rituximab, survivals are similar to recent European cohorts.

These observations provide necessary evidence that leading cancer centres around the world can benchmark their outcomes to those in high-income Western populations.

Acknowledgements: The study was made possible by financial and administrative support from the International Atomic Energy Agency.

Declaration of Interest statement: The authors declare no conflict of interest

REFERENCES

1. International Atomic Energy Agency - Coordinated Research Projects.
<http://www.iaea.org/monaco/page.php?page=2117>
2. Carr R, Fanti S, Paez D, Cerci J, Györke T, Redondo F, et al. Prospective international cohort study demonstrates inability of Interim PET to predict treatment failure in diffuse

- large B-Cell lymphoma. *J Nucl Med* 2014; **55**: 1936-1944.
3. Cheson BD, Pfistner B, Juweid M, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. *J Clin Oncol* 2007; **25**:579–586.
 4. Maurer MJ, Ghesquieres H, Jais J-S, Witzig TE, Haioun C, Thompson CA, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. *J Clin Oncol.* 2014; **32**:1066-1073
 5. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, et al. Prediction of survival in large-B-cell lymphoma based on the expression of six genes. *New Engl J Med* 2004; **350**:1828-1837.
 6. Malumbres R, Chen J, Tibshirani R, Johnson NA, Sehn LH, Natkunam Y, et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. *Blood* 2008; **111**:5509-5514
 7. Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Pocock C, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone in patients with newly diagnosed diffuse large B-cell lymphoma: a phase 3 comparison of intensification with 14-day versus 21-day cycles. *Lancet* 2013; **38**:1817–1826.
 8. Cavalli F. An appeal to world leaders: stop cancer now. *Lancet* 2013; **381**:425–426
 9. Naresh KN, Advani S, Adde M, Aziz Z, Banavali S, Bhatia K, et al. Report of an international network of cancer treatment and research workshop on non-Hodgkin lymphoma in developing countries. *Blood Cells Mol Dis* 2004; **33**:330-337
 10. Blinder V & Fisher SG. The role of environmental factors in the etiology of lymphoma. *Cancer Invest* 2008; **26**:306-316
 11. Park S, Lee J, Ko YH, Han A, Jun HJ, Lee SC, et al. The impact of Epstein-Barr virus status on clinical outcomes in diffuse large B-cell lymphoma. *Blood* 2007; **110**:972-978
 12. Morales D, Beltran B, de Mendoza F, Riva L, Yabar A, Quinones P, et al. Epstein-Barr virus as a prognostic factor in de nove nodal diffuse large B-cell lymphoma. *Leukaemia & Lymphoma* 2010; **51**:66-72

13. Okamoto A, Yanada M, Inaguma Y, Tokuda M, Morishima S, Kanie T, et al. The prognostic significance of EBV DNA load and EBER status in diagnostic specimens from diffuse large B-cell lymphoma patients. *Hematol Oncol* 2015; doi 10.1002/hon.2245
14. Hogfeldt T, Bahnassy AA, Kwiecinska A, Osterborg A, Tamm KP, Porwit A, et al. Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious areas have different inflammatory gene signatures. *Leukaemia & Lymphoma* 2013; **54**:996-1003
15. Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F, Gonzalez-Barca E, Mercadal S, Mate JL, et al. Gene-expression profiling and not immunophenotypic algorithms predict prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. *Blood* 2011; **117**: 4836-4843.
16. Reber R, Banz Y, Garamvolgyi E, Perren A, Novak U. Determination of the molecular subtypes of diffuse large B-cell Lymphoma using immunohistochemistry: a case series from the Inselspital, Bern, and a critical appraisal of this determination in Switzerland. *Swiss Med Wkly* 2013; **143**:w13748. Doi: 10.4414/smw.2013.13748

TABLE 1

Patient characteristic and 2y event free survival by country

	Chile	Hungary	India	Philippines	South Korea	Thailand	Turkey	All cases
Patients (<i>n</i>)	27	27	22	13	7	24	16	136
Age in years (<i>median</i>)	61	56	52	51	48	56	54	55
IPI 0–1	12 (44%)	18 (67%)	10 (45%)	4 (31%)	1 (14%)	9 (37%)	3 (19%)	42%
2	3 (11%)	2 (7%)	10 (45%)	3 (23%)	3 (43%)	6 (25%)	5 (31%)	24%
3	6 (22%)	5 (19%)	2 (9%)	4 (31%)	2 (29%)	6 (25%)	3 (19%)	21%
4–5	6 (22%)	2 (7%)	0 (0%)	2 (15%)	1 (14%)	3 (13%)	5 (31%)	14%
Treatment + Rituximab	26 (96%)	27 (100%)	14 (64%)	8 (62%)	7 (100%)	16 (67%)	16 (100%)	84%
2y EFS %	85%	80%	67%	66%	71%	74%	56%	73%

FIGURE LEGENDS

Figure 1

Composite of Kaplan-Meier plots showing event-free survival (EFS) for each country.





Figure 2

Heterogeneity of prognostic gene expression between countries.

A) Expression of the 6 individual prognostic genes for each study patient, by country.



B) Individual 6-gene scores, by country. Boxes represent median and inter-quartile range.





Figure 3


Kaplan-Meier EFS risk estimates for each country, generated from the Cox analysis.

A) Unadjusted survival risk estimates



B) Risk estimates, normalised to adjust for IPI.

(Note: Survival estimates for Hungary and S. Korea are superimposed in this figure)



C) Risk estimates, normalised to adjust for 6-gene scores.

